Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Dutasteride (02393220). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Dutasteride
All strengths: Limited Use, Reason for Use code 384, 385 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 384, 385 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Apo-Dutasteride · DIN 02404206 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Dutasteride · DIN 02404206
Manufacturer: Apotex Inc.; listing date 2014-09-25
Health Canada: Marketed since 2014-07-18 · brand APO-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02404206)
Source record
DIN 02404206: Apo-Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id APX
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02404206
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88899
Interchangeable products
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: active shortage (reported September 29, 2026, estimated to end October 16, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02404206
Shortage record checked October 6, 2026
Auro-Dutasteride · DIN 02469308 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Dutasteride · DIN 02469308
Manufacturer: Auro Pharma Inc.; listing date 2018-07-31
Health Canada: Marketed since 2018-06-04 · brand AURO-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02469308)
Source record
DIN 02469308: Auro-Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id AUR
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02469308
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95804
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended June 13, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469308
Shortage record checked October 6, 2026
Avodart · DIN 02247813 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Avodart (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Avodart · DIN 02247813
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2005-09-27
Health Canada: Marketed since 2003-11-14 · brand AVODART · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247813)
Source record
DIN 02247813: Avodart
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id GSK
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.2717; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247813
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72107
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247813
Shortage record checked October 6, 2026
Dutasteride · DIN 02429012 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Dutasteride · DIN 02429012
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2026-07-14 · brand DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordDutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02429012)
Source record
DIN 02429012: Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id SIV
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02429012
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91345
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended July 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429012
Shortage record checked October 6, 2026
Dutasteride · DIN 02443058 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Dutasteride · DIN 02443058
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2026-01-21 · brand DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordDutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443058)
Source record
DIN 02443058: Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id SAI
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443058
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92760
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: anticipated shortage (last updated October 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443058
Shortage record checked October 6, 2026
Jamp Dutasteride Capsules · DIN 02546167 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Dutasteride Capsules · DIN 02546167
Manufacturer: Jamp Pharma Corporation; listing date 2025-05-30
Health Canada: Marketed since 2025-03-17 · brand JAMP DUTASTERIDE CAPSULES · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Dutasteride Capsules: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546167)
Source record
DIN 02546167: Jamp Dutasteride Capsules
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id JPC
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546167
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103488
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546167
Shortage record checked October 6, 2026
Mint-Dutasteride · DIN 02428873 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Dutasteride · DIN 02428873
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-19 · brand MINT-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02428873)
Source record
DIN 02428873: Mint-Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id MIN
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02428873
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91334
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended February 22, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428873
Shortage record checked October 6, 2026
Priva-Dutasteride · DIN 02490587 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked November 18, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Priva-Dutasteride · DIN 02490587
Manufacturer: Pharmapar Inc.; listing date 2021-05-31
Health Canada: Marketed since 2024-01-02 · brand NRA-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPriva-Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02490587)
Source record
DIN 02490587: Priva-Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id PHP
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02490587
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98062
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02490587
Shortage record checked October 6, 2026
Sandoz Dutasteride · DIN 02424444 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Dutasteride · DIN 02424444
Manufacturer: Sandoz Canada Inc.; listing date 2014-09-25
Health Canada: Marketed since 2024-06-17 · brand SANDOZ DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02424444)
Source record
DIN 02424444: Sandoz Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id SDZ
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424444
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90912
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended April 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424444
Shortage record checked October 6, 2026
Teva-Dutasteride · DIN 02408287 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Dutasteride · DIN 02408287
Manufacturer: Teva Canada Limited; listing date 2014-09-25
Health Canada: Marketed since 2014-07-16 · brand TEVA-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02408287)
Source record
DIN 02408287: Teva-Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id TEV
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02408287
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89301
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Shortage status: resolved shortage (ended April 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408287
Shortage record checked October 6, 2026
Jamp Dutasteride · DIN 02484870 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredDormant since August 3, 2026 · checked October 5, 2026 · What does dormant mean? Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Dutasteride · DIN 02484870
Manufacturer: Jamp Pharma Corporation; listing date 2020-01-31
Health Canada: Dormant since 2026-08-03 · brand JAMP DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02484870)
Source record
DIN 02484870: Jamp Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id JPC
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02484870
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97515
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended June 4, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02484870
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.
Med-Dutasteride · DIN 02416298 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredDormant since July 22, 2026 · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Med-Dutasteride · DIN 02416298
Manufacturer: Generic Medical Partners Inc.; listing date 2014-12-18
Health Canada: Dormant since 2026-07-22 · brand MED-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Generic medical partners inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMed-Dutasteride: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2565). What the ministry pays, not the patient.
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416298)
Source record
DIN 02416298: Med-Dutasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id GMP
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2565; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416298
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90086
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Avodart · DIN 02247813 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended September 30, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416298
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 22, 2026 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (G04C, G04CB): coverage varies; not interchangeable
- Finasteride (Propecia): limited Use 384, 385, not a benefit
- Tamsulosin (Flomax CR Tab): general benefit, not a benefit
- Alfuzosin (Xatral): limited Use 351, 352
- Silodosin (Rapaflo): limited Use 351, 352, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered
Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE
Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL
92:00 UNCLASSIFIED THERAPEUTIC AGENTS
· 23 products · Off-Formulary Interchangeable, not an ODB benefit (8),
Limited Use, codes 384, 385 (15) · strengths: 1mg, 5mg · Tab
· 10 products · General benefit (9), Listed, not a benefit (1) · strengths: 0.4mg · ER Cap
· 6 products ·
Limited Use, codes 351, 352 · strengths: 10mg · Prolong-Rel Tab
· 10 products · Listed, not a benefit (2),
Limited Use, codes 351, 352 (8) · strengths: 4mg, 8mg · Cap
· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab
· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab
· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab
· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L
· 3 products · General benefit · strengths: 50mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab
· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab
· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00
and 78 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.